FrancophonIA/ELRC3.0 huggingface dataset:
English: DepoCyte is a suspension for injection that contains 50 mg of the active substance, cytarabine.
Slovenian: Zdravilo DepoCyte je suspenzija za injiciranje, ki vsebuje 50 mg zdravilne učinkovine citarabin.
English: This is a condition in which cells from a lymphoma (a tumour in the lymphatic system) have spread to the spinal fluid and the meninges (the membranes that surround the brain and spinal cord).
Slovenian: To je obolenje, pri katerem so se tumorske celice limfoma (tumorja v limfnem sistemu) razširile v spinalno tekočino in na meninge (membrane, ki obdajajo možgane in hrbtenjačo).
English: The most common side effects with DepoCyte (seen in more than 1 treatment cycle in 10) are headache, arachnoiditis (inflammation of one of the membranes protecting the spine and the brain), confusion, nausea (feeling sick), vomiting, diarrhoea, pyrexia (fever), weakness and thrombocytopenia (low blood platelet counts).To minimise the symptoms of arachnoiditis, patients should receive dexamethasone by mouth or by injection at the same time as DepoCyte and must be closely monitored.
Slovenian: Najpogostejši neželeni učinki zdravila DepoCyte (opaženi v več kot enem ciklu zdravljenja od 10) so glavobol, arahnoiditis (vnetje ene od membrane, ki varujejo hrbtenjačo in možgane), zmedenost, slabost, bruhanje, driska, preksija (povišana telesna temperatura), šibkost in trombocitopenija (nizke ravni trombocitov v krvi).
English: The full EPAR for DepoCyte can be found here.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo DepoCyte je na voljo tukaj.
English: This is then followed by maintenance doses of 50 mg every four weeks for a further four doses.
Slovenian: miligramski vzdrževalni odmerki vsake štiri tedne.
English: What is DepoCyte used for?
Slovenian: Za kaj se zdravilo DepoCyte uporablja ?
English: How has DepoCyte been studied?
Slovenian: Kako je bilo zdravilo DepoCyte raziskano?
English: How is DepoCyte used?
Slovenian: Kako se zdravilo DepoCyte uporablja?
English: What is DepoCyte?
Slovenian: Kaj je zdravilo DepoCyte?
English: How does DepoCyte work?
Slovenian: Kako zdravilo DepoCyte deluje?
English: 28 x 1 tablets
Slovenian: 98 tablets
English: Invented name Strength
Slovenian: Izmišljeni ime Jakost
English: Pharmaceutical Form Route of Administration Packaging
Slovenian: Farmacevtska oblika Pot uporabe
English: Dose adjustments might be necessary in these patients.
Slovenian: Pri teh bolnikih bo morda potrebna prilagoditev odmerka.
English: Gabapentin has been associated with severe respiratory depression.
Slovenian: Gabapentin je bil povezan s hudo respiratorno depresijo.
English: Gabapentin - Respiratory depression without concomitant opioid use (EPITT no 18814)
Slovenian: Gabapentin - respiratorna depresija brez sočasne uporabe opioidov (EPITT št. 18814)
English: Adopted at the 6-9 June 2017 PRAC
Slovenian: Sprejeto na seji odbora PRAC med 6. in 9. junijem 2017
English: What you need to know before you take <brand name> Warnings and precautions
Slovenian: Kaj morate vedeti, preden boste vzeli zdravilo <lastniško ime> Opozorila in previdnostni ukrepi
English: - if you have nervous system disorders, respiratory disorders, or you are more than 65 years old, your doctor may prescribe you a different dosing regimen
Slovenian: − če imate bolezni živčnega sistema, bolezni dihal ali ste stari več kot 65 let, vam bo zdravnik morda predpisal drugačno shemo odmerjanja
English: Respiratory depression
Slovenian: Dihalna depresija
English: In particular, tell your doctor (or pharmacist) if you are taking or have been recently taking any medicines for convulsions, sleeping disorders, depression, anxiety, or any other neurological or psychiatric problems.
Slovenian: Zlasti obvestite zdravnika (ali farmacevta), če jemljete ali ste pred kratkim jemali zdravila proti epileptičnim krčem (konvulzijam), motnjam spanja, depresiji, tesnobi ali kateri koli drugi nevrološki ali duševni motnji.
English: Contact your doctor immediately if you experience any of the following symptoms after taking this medicine as they can be serious:
Slovenian: Takoj obvestite zdravnika, če po jemanju zdravila opazite katerega koli od naslednjih simptomov, saj lahko predstavljajo resno stanje:
English: Patients with compromised respiratory function, respiratory or neurological disease, renal impairment, concomitant use of CNS depressants and the elderly might be at higher risk of experiencing this severe adverse reaction.
Slovenian: Bolniki z zmanjšano respiratorno funkcijo, boleznimi dihal ali nevrološkimi boleznimi, okvaro ledvic, sočasno uporabo zaviralcev osrednjega živčevja in starejši ljudje so lahko izpostavljeni večjemu tveganju za pojav tega hudega neželenega učinka.
English: New product information wording - Extracts from PRAC recommendations on signals EMA/PRAC/337624/2017
Slovenian: Novo besedilo informacij o zdravilu - izvlečki iz priporočil odbora PRAC o signalih EMA/PRAC/388994/2017
English: Undesirable effects Respiratory, thoracic and mediastinal disorders Frequency ‘rare': Respiratory depression
Slovenian: Bolezni dihal, prsnega koša in mediastinalnega prostora Pogostnost: „redki“: Respiratorna depresija
English: - breathing problems, which if severe you may need emergency and intensive care to continue breathing normally
Slovenian: − težave z dihanjem, pri katerih boste morda v primeru, da se pojavijo v hudi obliki, za vzpostavitev normalnega dihanja potrebovali nujno zdravniško pomoč in intenzivno nego
English: Summary of product characteristics 4.4.
Slovenian: Povzetek glavnih značilnosti zdravila
English: Special warnings and precautions for use Concomitant use with opioids
Slovenian: Posebna opozorila in previdnostni ukrepi
English: Talk to your doctor or pharmacist before taking <brand name>
Slovenian: Pred začetkom jemanja zdravila <lastniško ime> se posvetujte z zdravnikom ali farmacevtom
English: Rare (may affect up to 1 in 1,000 people):
Slovenian: Redki (pojavijo se lahko pri največ 1 od 1 000 bolnikov): − težave z dihanjem, plitvo dihanje (respiratorna depresija)
English: EU/1/18/1277/001 Mylotarg
Slovenian: EU/1/18/1277/001
English: Powder for concentrate for solution for infusion
Slovenian: 5 mg prašek za koncentrat za raztopino za infundiranje intravenska uporaba viala (steklo)
English: Pack size
Slovenian: Mylotarg
English: The patches should not be cut into pieces.
Slovenian: Ne smejo se rezati na manjše koščke.
English: The patches can be worn during bathing and hot weather.
Slovenian: Obliži se lahko nosijo med kopanjem in v vročem vremenu.
English: Treatment should be continued for as long as the patient benefits from it.
Slovenian: Zdravljenje je treba nadaljevati, dokler ima bolnik od njega koristi.
English: The patches are applied to clean, dry, hairless, intact skin on the back, upper arm or chest, and are replaced every 24 hours.
Slovenian: Obliže je treba prilepiti na čisto, suho, neporaščeno in nepoškodovano kožo na hrbtu, nadlakti ali prsih in zamenjati vsakih 24 ur.
English: Treatment should continue as long as the medicine has a benefit, but the dose can be reduced or treatment interrupted if the patient has side effects.
Slovenian: Zdravljenje je treba nadaljevati, dokler ima zdravilo koristi, vendar se lahko odmerek zmanjša ali zdravljenje prekine, če se pri bolniku pojavijo neželeni učinki.
English: They should not be placed on irritated or red skin, on the thigh or abdomen (tummy), or in places where they will be rubbed by tight clothing.
Slovenian: Ne smejo se prilepiti na razdraženo ali pordelo kožo, na stegno ali trebuh in na predele, kjer bi se drgnili ob tesna oblačila.
English: The full EPAR and risk management plan summary for Rivastigmine 3M Health Care Ltd can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Rivastigmin 3M Health Care Ltd sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This is a summary of the European public assessment report (EPAR) for Rivastigmine 3M Health Care Ltd.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Rivastigmin 3M Health Care Ltd.
English: Treatment should be started with the 4.6-mg-per-24-hours patch, with the dose increased to the higher strength 9.5 mg/24-h patch after at least four weeks if the lower dose is well tolerated.
Slovenian: Zdravljenje je treba začeti z obližem, ki v 24 urah sprosti 4,6 mg učinkovine, po najmanj štirih tednih pa je treba odmerek povečati na 9,5 mg/24 ur z uporabo obliža večje jakosti, če bolnik manjši odmerek dobro prenaša.
English: In patients with Alzheimer's dementia, certain nerve cells die in the brain, resulting in low levels of the neurotransmitter acetylcholine (a substance that allows nerve cells to communicate with each other).
Slovenian: Pri bolnikih z Alzheimerjevo demenco nekatere živčne celice v možganih odmrejo, zaradi česar se znižajo ravni živčnega prenašalca acetilholina (kemične snovi, ki omogoča medsebojno komunikacijo
English: Rivastigmine 3M Health Care Ltd can only be obtained with a prescription and is available as transdermal patches, which release either 4.6 or 9.5 mg rivastigmine across the skin over 24 hours.
Slovenian: Izdaja zdravila Rivastigmin 3M Health Care Ltd je le na recept, na voljo pa je v obliki transdermalnih obližev, ki v 24 urah skozi kožo sprostijo 4,6 ali 9,5 mg rivastigmina.
English: Treatment with Rivastigmine 3M Health Care Ltd should be started and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer's dementia.
Slovenian: Zdravljenje z zdravilom Rivastigmin 3M Health Care Ltd mora uvesti in nadzorovati zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem Alzheimerjeve demence.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Rivastigmine 3M Health Care Ltd has been shown to have comparable quality and to be bioequivalent to Exelon.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Rivastigmin 3M Health Care Ltd primerljivo raven kakovosti kot referenčno zdravilo Exelon ter da mu je biološko enakovredno.
English: Because Rivastigmine 3M Health Care Ltd is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Slovenian: Ker je zdravilo Rivastigmin 3M Health Care Ltd generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
English: The Committee recommended that Rivastigmine 3M Health Care Ltd be approved for use in the EU.
Slovenian: Priporočil je, da se zdravilo Rivastigmin 3M Health Care Ltd odobri za uporabo v EU.
English: This means that Rivastigmine 3M Health Care Ltd is similar to a ‘reference medicine' already authorised in the European Union (EU) called Exelon.
Slovenian: To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Exelon.
English: Patients can be switched from rivastigmine capsules or oral solution to the patches.
Slovenian: Bolniki, ki jemljejo kapsule ali peroralno raztopino rivastigmina, lahko preidejo na zdravljenje z obliži.
English: What measures are being taken to ensure the safe and effective use of Rivastigmine 3M Health Care Ltd?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Rivastigmin 3M Health Care Ltd?
English: For more information about treatment with Rivastigmine 3M Health Care Ltd, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Rivastigmin 3M Health Care Ltd preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: Rivastigmine 3M Health Care Ltd is used to treat patients with mild to moderately severe Alzheimer's dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour.
Slovenian: Uporablja se za zdravljenje bolnikov z blago do zmerno hudo Alzheimerjevo demenco, tj. napredujočo možgansko boleznijo, ki postopoma prizadene spomin, intelektualno sposobnost in vedenje.
English: Treatment should only be started if a caregiver is available who will regularly give and monitor the use of Rivastigmine 3M Health Care Ltd by the patient.
Slovenian: Zdravljenje se sme uvesti samo, če je na voljo negovalec, ki bo redno dajal zdravilo Rivastigmin 3M Health Care Ltd in spremljal njegovo uporabo pri bolniku.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Rivastigmine 3M Health Care Ltd on 3 April 2014.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Rivastigmin 3M Health Care Ltd, veljavno po vsej Evropski uniji, izdala 03. aprila 2014.
English: The active substance in Rivastigmine 3M Health Care Ltd, rivastigmine works by blocking the enzymes that break down acetylcholine: acetylcholinesterase and butyrylcholinesterase.
Slovenian: Zdravilna učinkovina v zdravilu Rivastigmin 3M Health Care Ltd, rivastigmin, deluje tako, da zavira encime, ki razgrajujejo acetilholin: acetilholinesterazo in butirilholinesterazo.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Rivastigmine 3M Health Care Ltd, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila Rivastigmin 3M Health Care Ltd in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: Because Rivastigmine 3M Health Care Ltd is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Exelon.
Slovenian: Ker je zdravilo Rivastigmin 3M Health Care Ltd generično zdravilo, so bile študije pri ljudeh omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Exelon.
English: Other information about Rivastigmine 3M Health Care Ltd
Slovenian: Druge informacije o zdravilu Rivastigmin 3M Health Care Ltd
English: By blocking these enzymes, Rivastigmine 3M Health Care Ltd allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer's dementia.
Slovenian: Zdravilo Rivastigmin 3M Health Care Ltd z zaviranjem teh encimov povzroči, da se ravni acetilholina v možganih zvišajo, zaradi česar se simptomi Alzheimerjeve demence ublažijo.
English: Rivastigmine 3M Health Care Ltd is a medicine that contains the active substance rivastigmine.
Slovenian: Rivastigmin 3M Health Care Ltd je zdravilo, ki vsebuje zdravilno učinkovino rivastigmin.
English: For practical information about using Rivastigmine 3M Health Care Ltd, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Rivastigmin 3M Health Care Ltd naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: Therefore, the CHMP's view was that, as for Exelon, the benefit outweighs the identified risk.
Slovenian: Zato je menil, da njegove koristi enako kot pri zdravilu Exelon odtehtajo znana tveganja.
English: A risk management plan has been developed to ensure that Rivastigmine 3M Health Care Ltd is used as safely as possible.
Slovenian: Za zagotovitev čim varnejše uporabe zdravila Rivastigmin 3M Health Care Ltd je bil pripravljen načrt obvladovanja tveganj.
English: Rivastigmine 3M Health Care Ltd is a ‘generic medicine'.
Slovenian: Zdravilo Rivastigmin 3M Health Care Ltd je „generično zdravilo“.
English: What is Rivastigmine 3M Health Care Ltd and what is it used for?
Slovenian: Kaj je zdravilo Rivastigmin 3M Health Care Ltd in za kaj se uporablja?
English: What are the benefits and risks of Rivastigmine 3M Health Care Ltd?
Slovenian: Kakšne so koristi in tveganja, povezani z zdravilom Rivastigmin 3M Health
English: Why is Rivastigmine 3M Health Care Ltd approved?
Slovenian: Zakaj je bilo zdravilo Rivastigmin 3M Health Care Ltd odobreno?
English: The full EPAR for the reference medicine can also be found on the Agency's website.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za referenčno zdravilo je tudi na voljo na
English: How does Rivastigmine 3M Health Care Ltd work?
Slovenian: Kako zdravilo Rivastigmin 3M Health Care Ltd deluje?
English: How has Rivastigmine 3M Health Care Ltd been studied?
Slovenian: Kako je bilo zdravilo Rivastigmin 3M Health Care Ltd raziskano?
English: How is Rivastigmine 3M Health Care Ltd used?
Slovenian: Kako se zdravilo Rivastigmin 3M Health Care Ltd uporablja?
English: Article 35 of Directive 2001/82/EC, as amended.
Slovenian: Člen 35 Direktive 2001/82/ES, kakor je bila spremenjena.
English: The CVMP was requested to give its opinion on the matter.
Slovenian: CVMP je bil naprošen, da o zadevi izrazi svoje mnenje.
English: International Non-Proprietary Name (INN): Ivermectin
Slovenian: Mednarodno nelastniško ime (INN): ivermektin
English: The final opinion was converted into a Decision by the European Commission on 1 October 2009.
Slovenian: Končno mnenje je bilo spremenjeno v Odločbo Evropske komisije dne 1 oktobra 2009.
English: 1 October 2009 Doc.
Slovenian: 1 oktober 2009 Sklic dok.
English: The referral procedure started on 16 January 2008.
Slovenian: Napotitveni postopek se je začel 16. januarja 2008.
English: Ref. EMEA/471056/2009
Slovenian: : EMEA/471056/2009
English: The submitted information concerned 173 of the 293 Marketing Authorisations involved in this referral procedure.
Slovenian: Predložene informacije so zadevale 173 od 293 dovoljenj za promet, ki jih obravnava zadevni napotitveni postopek.
English: On 9 December 2008 and 14 January 2009 two Marketing Authorisation Holders provided oral explanations at their request.
Slovenian: 9. decembra 2008 in 14. januarja 2009 sta dva imetnika dovoljenj za promet na njihovo zahtevo podala ustna pojasnila.
English: On 4 June 2008 the National Competent Authorities of the Member States were requested to provide the missing information for the outstanding 120 Marketing Authorisations.
Slovenian: 4. junija 2008 so bili nacionalni pristojni organi držav članic naprošeni, naj priskrbijo manjkajoče informacije za preostalih 120 dovoljenj za promet.
English: National Marketing Authorisations for injectable products containing ivermectin for use in cattle have been granted in all the Member States of the European Union via different authorisation procedures (mutual recognition procedures or national procedures) and under various legal bases.
Slovenian: Nacionalna dovoljenja za promet z zdravili za injiciranje, ki vsebujejo ivermektin za uporabo pri govedu, so bila odobrena v vseh državah članicah Evropske unije z različnimi postopki izdaje dovoljenj (postopki medsebojnega priznavanja ali nacionalnimi postopki) ali v skladu z različnimi pravnimi podlagami.
English: On 17 September 2008 the CVMP considered that there were still issues with regard to some products which needed further clarification and therefore the Committee requested the relevant Marketing Authorisation Holders to address the outstanding issues in writing.
Slovenian: 17. septembra 2008 je CVMP menil, da nekatera vprašanja v zvezi z nekaterimi zdravili še ostajajo in zahtevajo nadaljnja pojasnila, zato je Odbor zadevne imetnike dovoljenj za promet zaprosil, naj pisno pojasnijo preostala vprašanja.
English: Based on the evaluation of the currently available data and the rapporteurs' assessment, the CVMP considered that its opinion of 11 February 2009 should be revised.
Slovenian: Na podlagi ovrednotenja trenutno razpoložljivih podatkov in poročevalčevih ocen je CVMP menil, da je treba mnenje z dne 11. februarja 2009 revidirati.
English: During its 10-12 March 2009 meeting, the CVMP, appointed Dr A. Holm as rapporteur and Dr M. Holzhauser-Alberti as co-rapporteur for the re-examination of the above mentioned opinion.
Slovenian: Na zasedanju CVMP od 10. do 12. marca 2009 je bil dr. A. Holm imenovan za poročevalca in dr. M. Holzhauser-Alberti za soporočevalca v postopku ponovne presoje zgoraj omenjenega mnenja.
English: On 25 February 2009, Norbrook Laboratories Ltd, notified the EMEA of its intention to request the reexamination of the CVMP opinion of 11 February 2009.
Slovenian: Dne 25. februarja 2009 je družba Norbrook Laboratories Ltd obvestila agencijo EMEA, da namerava zaprositi za ponovno presojo mnenja CVMP z dne 11. februarja 2009.
English: The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the amended Summary of Product Characteristics, package leaflet and label in the Annex III.
Slovenian: Seznam zadevnih imen proizvodov je naveden v Dodatku I. Znanstveni zaključki so podani v Dodatku II, skupaj s spremenjenim povzetkom glavnih značilnosti zdravila, označevanjem in navodilom za uporabo v Dodatku III.
English: Due to concerns that the difference in withdrawal periods established across the European Union for injectable veterinary medicinal products containing ivermectin which are indicated for use in cattle and with a dose of 200µg ivermectin/kg bodyweight may present a potential serious risk to human health, the United Kingdom referred the matter to the EMEA on 14 December 2007, under Article 35 of Directive 2001/82/EC.
Slovenian: Zaradi zaskrbljenosti, da bi lahko razlike v karencah, določenih v različnih državah Evropske unije za veterinarska zdravila za injiciranje, ki vsebujejo ivermektin in so indicirana za uporabo pri govedu v odmerku 200µg ivermektina/kg telesne mase, utegnile predstavljati morebitno resno tveganje za zdravje ljudi, je Združeno kraljestvo zadevo napotilo na agencijo EMEA dne 14. decembra 2007, v skladu s členom 35 Direktive 2001/82/ES.
English: Eighteen Member States responded and submitted information concerning 103 of the outstanding 120 Marketing Authorisations.
Slovenian: Odgovorilo je 18 držav članic in predložilo informacije v zvezi s 103 od manjkajočih 120 dovoljenj za promet.
English: The Committee appointed Dr G. J. Schefferlie as rapporteur and Dr J. G. Beechinor, Prof C. Friis, Prof R. Kroker and Dr B. Urbain as co-rapporteurs.
Slovenian: Schefferlie je bil imenovan za poročevalca, dr. J. G. Beechinor, prof. C. Friis, prof. R. Kroker and dr. B. Urbain pa za soporočevalce.
English: On 21 May 2008 the EMEA received a total of 19 written explanations from the Marketing Authorisation Holders (either as a group of or individual Marketing Authorisation Holders).
Slovenian: 21. maja 2008 je EMEA od imetnikov dovoljenj za promet z zdravilom (skupinskih ali posameznih imetnikov dovoljenj za promet) prejela skupaj 19 pisnih obrazložitev.
English: Written explanations were provided by the Marketing Authorisation Holders on 13 November 2008.
Slovenian: Imetniki dovoljenja za promet z zdravilom so pisna pojasnila predložili dne 13. novembra 2008.
English: Ivermectin belongs to the macrocyclic lactone class of endectocides with activity against a wide rage of internal and external parasites.
Slovenian: Ivermektin sodi v skupino makrocikličnih laktonov v okviru endektocitov, ki delujejo proti številnim vrstam notranjih in zunanjih parazitov.
English: Further to the resignation of Prof R. Kroker as CVMP member, Dr C. Ibrahim was appointed to replace him and took over the co-rapporteurship.
Slovenian: Ker je prof. R. Kroker odstopil z mesta člana odbora CVMP, je bil na njegovo mesto imenovan dr. C. Ibrahim, ki je prevzel soporočevalstvo.